

Connecticut Pub. Act 23-171 Disclosure

WELIREG™ (belzutifan)

Merck Sharp & Dohme LLC (“Merck”) provides the following information to Connecticut prescribers, in accordance with Conn. Pub. Act 23-171.

The pricing information below reflects Merck’s Wholesale Acquisition Costs (“WAC”) for the Merck product(s) listed below. The WAC represents published catalogue or list price and may not represent actual transactional prices.

The price a customer pays may vary from the price(s) listed, depending, for example, on how the customer purchases the product(s), the availability of discounts, the wholesaler/distributor, and/or other charges.

WAC for Merck Product

PRODUCT	NDC	DOSAGE FORM AND STRENGTH	WHOLESALE ACQUISITION COST (WAC)
WELIREG™ (belzutifan) 40 mg Tablets	00006-5331-01	Unit-of-use bottle of 90	\$29,661.30

Additional Information

In accordance with Conn. Pub. Act No. 23-171, Sec. 5(2), for information on efficacy by racial and ethnic group for the product(s) listed above, if available, please refer to the United States Food and Drug Administration (“FDA”) approved Prescribing Information and/or the FDA’s Drug Trials Snapshots database (available online at <https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots>).

Copies of the Prescribing Information are available through the Merck representative who has provided you with this disclosure form as well as online at Merckconnect.com or Merckvaccines.com (for vaccines only).

The trademarks or service marks herein are owned by, licensed to, promoted by, or distributed by Merck & Co., Inc., its subsidiaries or its affiliates.

Copyright © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

US-BEL-00998 01/24